Overall, these results suggest that mTOR inhibition of RCC cells upregulates MEK/ERK signaling and that catalytic mTOR inhibition may do so in a more robust manner than allosteric inhibition. This evidence concerns the gene MAP2K7 and renal cell carcinoma.